COMBINATION THERAPY COMPRISING AN FFAR4 AGONIST AND AN ALPHA-7 NACHR AGONIST OR POSITIVE… Application WO-2020212627-A1 World Intellectual Property Organisation (WIPO) 22 Oct 2020